1-6 of 6
Bart J. Biemond
Close
Sort by
Journal Articles

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study

Clinical Trials & Observations
Myrthe J. van Dijk, Minke A. E. Rab, Brigitte A. van Oirschot, Jennifer Bos, Cleo Derichs, Anita W. Rijneveld, Marjon H. Cnossen, Erfan Nur, Bart J. Biemond, Marije Bartels, Judith J. M. Jans, Wouter W. van Solinge, Roger E. G. Schutgens, Richard van Wijk, Eduard J. van Beers
Journal: Blood Advances
Blood Adv (2023) 7 (24): 7539–7550.
https://doi.org/10.1182/bloodadvances.2023011477
Published: 2023
Includes: Supplemental data
Journal Articles

Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study

Rajani P. Brandsen, Roselie M. H. Diederen, Siham Bakhlakh, Erfan Nur, Reinier O. Schlingemann, Bart J. Biemond
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3080–3086.
https://doi.org/10.1182/bloodadvances.2022009147
Published: 2023
Journal Articles

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

Clinical Trials & Observations
Anita W. Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J. Biemond, Arjen A. van de Loosdrecht, Lotte E. van der Wagen, Mar Bellido, Michel van Gelder, Walter J. F. M. van der Velden, Dominik Selleslag, Daniëlle van Lammeren-Venema, Constantijn J. M. Halkes, Rob Fijnheer, Violaine Havelange, Geerte L. van Sluis, Marie-Cecile Legdeur, Dries Deeren, Alain Gadisseur, Harm A. M. Sinnige, Dimitri A. Breems, Aurélie Jaspers, Ollivier Legrand, Wim E. Terpstra, Rinske S. Boersma, Dominiek Mazure, Agnes Triffet, Lidwine W. Tick, Karolien Beel, Johan A. Maertens, H. Berna Beverloo, Marleen Bakkus, Christa H. E. Homburg, Valerie de Haas, Vincent H. J. van der Velden, Jan J. Cornelissen, the Dutch-Belgian HOVON Cooperative group
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1115–1125.
https://doi.org/10.1182/bloodadvances.2021005624
Published: 2022
Includes: Supplemental data
Journal Articles

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Clinical Trials & Observations
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri A. Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjorn T. Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J. M. Valk, Catharina H. M. J. van Elssen, Markus G. Manz, Yngvar Floisand, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1110–1121.
https://doi.org/10.1182/bloodadvances.2020003855
Published: 2021
Includes: Supplemental data
Journal Articles

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms

Eva N. Hamulyák, Joost G. Daams, Frank W. G. Leebeek, Bart J. Biemond, Peter A. W. te Boekhorst, Saskia Middeldorp, Mandy N. Lauw
Journal: Blood Advances
Blood Adv (2021) 5 (1): 113–121.
https://doi.org/10.1182/bloodadvances.2020003628
Published: 2021
Includes: Supplemental data
Journal Articles

Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review

Clinical Trials & Observations
Joep W. R. Sins, David J. Mager, Shyrin C. A. T. Davis, Bart J. Biemond, Karin Fijnvandraat
Journal: Blood Advances
Blood Adv (2017) 1 (19): 1598–1616.
https://doi.org/10.1182/bloodadvances.2017007211
Published: 2017
Includes: Supplemental data